Harmonization of reimbursement and regulatory approval processes: a systematic review of international experiences
暂无分享,去创建一个
Ron Goeree | Michael Drummond | Bernice Tsoi | Kaitryn Campbell | Daria O'Reilly | M. Drummond | R. Goeree | D. O'Reilly | K. Campbell | Lisa Masucci | B. Tsoi | L. Masucci
[1] Ruth Ellen Bulger,et al. The Institute of Medicine , 1992, JAMA.
[2] P. Villeneuve. The Placebo Standard in Regulatory Market Approval: Why the Declaration of Helsinki Has Been Ignored for 35 years , 2020 .
[3] Doug Coyle,et al. The Potential Impact Of Recommendations Made Through The Common Drug Review Program At The Canadian Agency For Drugs And Technologies In Health , 2014 .
[4] I. Wiklund,et al. Health economics and outcomes research within drug development: challenges and opportunities for reimbursement and market access within biopharma research. , 2012, Drug discovery today.
[5] J. Belsey,et al. Addressing the health technology assessment of biosimilar pharmaceuticals , 2010, Current medical research and opinion.
[6] K. Tolley. Pharmaceutical market access and the challenges of health technology assessment in the United Kingdom , 2010 .
[7] R. Barker. A flexible blueprint for the future of drug development , 2010, The Lancet.
[8] Michael Drummond,et al. Economic evaluation for devices and drugs--same or different? , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[9] Marc L. Berger,et al. Comparative Effectiveness Research , 2012, PharmacoEconomics.
[10] J. Hutton,et al. The feasibility of harmonizing health technology assessments across jurisdictions: A case study of drug eluting stents , 2009, International Journal of Technology Assessment in Health Care.
[11] Malcolm Rowland,et al. Bridging the efficacy–effectiveness gap: a regulator's perspective on addressing variability of drug response , 2011, Nature Reviews Drug Discovery.
[12] Martin McKee,et al. Ensuring Value for Money in Health Care: The Role of Health Technology Assessment in the European Union , 2008 .
[13] F. Pichler,et al. INTERACTION INITIATIVES BETWEEN REGULATORY, HEALTH TECHNOLOGY ASSESSMENT AND COVERAGE BODIES, AND INDUSTRY , 2012, International Journal of Technology Assessment in Health Care.
[14] R. Epstein,et al. Integrating new approaches for clinical development: translational research and relative effectiveness. , 2012, Journal of comparative effectiveness research.
[15] M. Drummond,et al. Early dialogue between the developers of new technologies and pricing and reimbursement agencies: a pilot study. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[16] Rebecca S. Graves,et al. Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice. , 2002 .
[17] S. Walker,et al. Preparing for Regulatory Review and Reimbursement Decisions , 2009, Pharmaceutical Medicine.
[18] J. Abraham. The international conference on harmonisation of technical requirements for registration of pharmaceuticals for human use , 2009 .
[19] Katrine Frønsdal,et al. Interactions between health technology assessment, coverage, and regulatory processes: Emerging issues, goals, and opportunities , 2011, International Journal of Technology Assessment in Health Care.
[20] J. Iglehart,et al. Centers for Medicare and Medicaid Services , 2020, Definitions.
[21] J. Samet,et al. Food and Drug Administration , 2007, BMJ : British Medical Journal.
[22] H. Eichler,et al. Adaptive Licensing: Taking the Next Step in the Evolution of Drug Approval , 2012, Clinical pharmacology and therapeutics.
[23] Steven Pearson,et al. Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers , 2010, Nature Reviews Drug Discovery.